Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
OTC PK
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Net Income | 98.34% | 89.77% | 98.84% | 76.85% | -1,188.67% |
| Total Depreciation and Amortization | 102.41% | -98.93% | 87.06% | 159.32% | -10,128.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.09% | -100.06% | -109.84% | -104.78% | 796.07% |
| Change in Net Operating Assets | 46.62% | 452.40% | -86.12% | 97.21% | 89.03% |
| Cash from Operations | 365.00% | 302.31% | -51.40% | 51.94% | -169.12% |
| Capital Expenditure | -1.47% | -- | 72.65% | 96.30% | -166.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 373,085.00% | -280.33% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -473.08% | -46.76% | 112.94% | -- | -1,905,300.00% |
| Cash from Investing | -762.58% | -- | 109.88% | 61.33% | -1,090.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -100.00% | -99.43% | 1,003.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -100.00% | -100.00% | -99.45% | 145.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.21% | 13.66% | 169.95% | -118.18% | -411.06% |